1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Force Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. NORTH AMERICA CONTINUOUS GLUCOSE MONITORING (CGM) MARKET, BY APPLICATION
5.1. Introduction
5.2. Diabetes Patients
5.3. Critical Patients
6. NORTH AMERICA CONTINUOUS GLUCOSE MONITORING (CGM) MARKET, BY END-USER INDUSTRY
6.1. Introduction
6.2. Hospitals
6.3. Diagnostic Centers & Clinics
6.4. Home Care
7. NORTH AMERICA CONTINUOUS GLUCOSE MONITORING (CGM) MARKET, BY COUNTRY
7.1. Introduction
7.2. United States
7.3. Canada
7.4. Mexico
8. COMPETITIVE ENVIRONMENT AND ANALYSIS
8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrativeness
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix
9. COMPANY PROFILES
9.1. Dexcom Inc.
9.2. Abbott Laboratories
9.3. Medtronic plc
9.4. Senseonics Holdings Inc.
9.5. Tandem Diabetes Care Inc.
9.6. Insulet Corporation
9.7. Ascensia Diabetes Care Holdings AG
9.8. Ypsomed AG
9.9. Roche Diabetes Care Inc.
9.10. GlySens Incorporated